Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TSN222
i
Other names:
TSN222
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Tyligand
Drug class:
STING agonist
Related drugs:
‹
CS-1018 (2)
XMT-2056 (2)
CS-1010 (1)
CS-1020 (1)
TAK-500 (1)
ACTM-838 (0)
ADU-S100 (0)
BI 1387446 (0)
E7766 (0)
GSK3745417 (0)
IMSA101 (0)
MK-2118 (0)
ONM-501 (0)
SB 11285 (0)
SYNB1891 (0)
TAK-676 (0)
exoSTING (0)
MK-1454 (0)
CS-1018 (2)
XMT-2056 (2)
CS-1010 (1)
CS-1020 (1)
TAK-500 (1)
ACTM-838 (0)
ADU-S100 (0)
BI 1387446 (0)
E7766 (0)
GSK3745417 (0)
IMSA101 (0)
MK-2118 (0)
ONM-501 (0)
SB 11285 (0)
SYNB1891 (0)
TAK-676 (0)
exoSTING (0)
MK-1454 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
P1/2, N=162, Recruiting, Tyligand Bioscience (Shanghai) Limited | Not yet recruiting --> Recruiting
7 months ago
Enrollment open • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
TSN222
over1year
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
P1/2, N=162, Not yet recruiting, Tyligand Bioscience (Shanghai) Limited
over 1 year ago
New P1/2 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
TSN222
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login